Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Ladenburg Thalmann analyst Kevin DeGeeter maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $27 to $31.
Ladenburg Thalmann analyst Kevin DeGeeter maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $27 to $31.